SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study

Journal of Experimental & Clinical Cancer Research

Pietro Donati³  Stefania Bucher²  Caterina Catrical๠ Giovanni Paolino³  Flavio Andrea Govoni⁴  Barbara Bellei⁵  Emilia Migliano² 

[1] Department of Dermatology-Oncology, San Gallicano Dermatologic Institute, Rome, Italy;Department of Plastic and Reconstructive Surgery, San Gallicano Dermatologic Institute, Rome, Italy;Dermatopathology Unit, San Gallicano Dermatologic Institute, Rome, Italy;Department of Maxillofacial Surgery, San Filippo Neri Hospital, Rome, Italy;Laboratory of Cutaneous Physiopathology, San Gallicano Dermatologic Institute, Rome, Italy

关键词: Nodal status;    Melanoma micrometastasis;    Starz classification;    CLND;    SLN;    Sentinel lymph node;   

Others  :  824840
DOI  :  10.1186/1756-9966-32-47

 received in 2013-06-04, accepted in 2013-07-26,  发布年份 2013

【 摘 要 】

Background

Completion lymph node dissection (CLND) is the gold standard treatment for patients with a positive sentinel lymph node (SLN) biopsy. Considering the morbidity associated with CLND it is important to identify histological features of the primary tumor and/or of SLN metastasis that could help to spare from CLND a subset of patients who have a very low risk of non-SLN metastasis. The objective of this study is to identify patients with a very low risk to develop non-SLNs recurrences and to limit unnecessary CLND.

Methods

A retrospective long-term study of 80 melanoma patients with positive SLN, undergone CLND, was assessed to define the risk of additional metastasis in the regional nodal basin, on the basis of intranodal distribution of metastatic cells, using the micro-morphometric analysis (Starz classification).

Results

This study demonstrates that among the demographic and pathologic features of primary melanoma and of SLN only the Starz classification shows prognostic significance for non-SLN status (p<0.0001). This parameter was also significantly associated with disease-free survival rate (p<0.0013).

Conclusion

The Starz classification can help to identify, among SLN positive patients, those who can have a real benefit from CLND. From the clinical point of view this easy and reliable method could lead to a significant reduction of unnecessary CLND in association with a substantial decrease in morbidity. The study results indicate that most of S1 subgroup patients might be safely spared from completion lymphatic node dissection. Furthermore, our experience demonstrated that Starz classification of SLN is a safe predictive index for patient stratification and treatment planning.

【 授权许可】

   
2013 Migliano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 27:392-399.
• [2]Thompson JF, McCarthy WH, Bosch CM, O’Brien CJ, Quinn MJ, Paramaesvaran S, Crotty K, McCharty SW, Uren RF, Howman-Giles R: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995, 5:255-260.
• [3]Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
• [4]Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, Cavaliere R, Mozzillo N, Rossi CR, MacKie RM, Nieweg O, Pace M, Kirov K: Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000, 7:469-474.
• [5]Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang H, Multicenter Selective Lymphadenectomy Trial Group: Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242:302-311. discussion 311–313
• [6]Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI: Microscopic tumor burden in non sentinel lymph nodes predicts synchronous non sentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008, 26:4296-4303.
• [7]Pasquali S, Mocellin S, Campana LG, Bonandini E, Montesco MC, Tregnaghi A, Del Fiore P, Nitti D, Rossi CR: Early (Sentinel Lymph Node Biopsy-Guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases. Cancer 2010, 116:1201-1209.
• [8]Starz H, Siedleki K, Balda BR: Sentinel lymphadenectomy and S- classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004, 11:162S-168S.
• [9]Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, Pijpers R, Morton DL: The Ausburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and Completion lymphadenectomy in cutaneous malignancies. Cancer 2000, 89:236-241.
• [10]Satzger I, Völker B, Meier A, Schenck F, Kapp A, Gutzmer R: Prognostic significance of isolated HM45 or melan A positive cells in melanoma sentinel lymph nodes. Am J Surg Pathol 2007, 31:1175-1180.
• [11]Starz H: Pathology of sentinel lymph node in melanoma. Semin Oncol 2004, 31:357-362.
• [12]Starz H, Balda BR, Kramer KU, Büchels H, Wang H: A micromorphometric-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001, 91:2110-2121.
• [13]Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, Ruzicka T, Berking C, Schmid-Wendtner MH: Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. J Am Acad Dermatol 2011, 64:655-662.
• [14]van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M: Clinical relevance of melanoma micrometastases (<0,1 mm) in sentinel lymph node. Are these nodes to be considered negative? Ann Oncol 2006, 17:1578-1585.
• [15]Testori A, De Salvo G, Montesco MC, Trifirò G, Mocellin S, Landi G, Macripò G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR, Italian Melanoma Intergroup: Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1313 Patients (SOLISM –IMI). Ann Surg Oncol 2009, 16(7):2018-2027.
• [16]Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 335:1307-1317.
• [17]Quaglino P, Ribero S, Osella-Abate S, Macrì L, Grassi M, Caliendo V, Asioli S, Sapino A, Macripò G, Savoia P, Bernengo MG: Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: a single centre observational cohort study. Surg Oncol 2010, 20:259-264.
• [18]Rossi CR, De Salvo GL, Bonandini E, Mocellin S, Foletto M, Pasquali S, Pilati P, Lise M, Nitti D, Rizzo E, Montesco MC: Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 2008, 15:1202-1208.
• [19]Fournier K, Schiller A, Perry RR, Laronga C: Micrometastasis in the sentinel lymph node of breast cancer cancer does not mandate completion axillary dissection. Ann Surg 2004, 239:859-863.
• [20]Rutgers EJ: Sentinel node micrometastasis in breast cancer. Br J Surg 2004, 91:1241-1242.
• [21]Dewar DJ, Newell B, Green MA, Topping AP, Powell BW, Cook MG: The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts non-sentinel lymph node involvement. J Clin Oncol 2004, 22:3345-3349.
• [22]Roka F, Mastan P, Binder M, Okamoto I, Mittlboeck M, Horvat R, Pehamberger H, Diem E: Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 2008, 34:82-88.
• [23]Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL: Prediction of metastatic melanoma in non-sentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004, 17:747-755.
• [24]Wagner JD, Gordon MS, Chuang TY, Coleman JJ 3rd, Hayes JT, Jung SH, Love C: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000, 89:453-462.
• [25]Sabel MS, Griffith K, Sondak VK: Predictors of non sentinel lymph node positivity in patients with a positives sentinel node for melanoma. J Am Coll Surg 2005, 201:37-47.
• [26]Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG: Prediction of non-sentinel lymph node status in melanoma. Ann Surg Oncol 2003, 10:27-31.
• [27]Frankel TL, Griffith KA, Lowe L, Wong SL, Bichakjian CK, Chang AE, Cimmino VM, Bradford CR, Rees RS, Johnson TM, Sabel MS: Do micromorphometric features of metastatic deposits within sentinel nodes predict non sentinel lymph node involvement in melanoma? Ann Surg Oncol 2008, 15:2403-2411.
• [28]van der Ploeg IM, Kroon BB, Antonini N, Valdés Olmos RA, Nieweg OE: Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg 2009, 249:1003-1007.
• [29]Van der Ploeg IM, Kroon BB, Antonini N, Valdés Olmos RA, Nieweg OE: Comparison of three micromorphometric pathology classifications of melanoma metastasis in the sentinel node. Ann Surg 2009, 250:301-304.
• [30]Bogenriender T, van Dijk MR, Bloky WA, Ramrath K, Seldenrijk K, Stolz W, van Diest PJ: No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumor load. Histopathol 2011, 59:318-326.
• [31]Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of, 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
• [32]Murali R, Cochran AJ, Cook MG, Hillman JD, Karim RZ, Moncrieff M, Starz H, Thompson JF, Scolyer RA: Inter-observer reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer 2009, 115:5026-5037.
• [33]Veenstra HJ, Brouwer OR, van der Ploeg IM, Kroon BB, Nieweg OE: Five-year follow-up of 16 melanoma patients with a Starz I-involved sentinel node in whom completion lymph node dissection was omitted. Melanoma Res 2012, 22(6):436-439.
• [34]Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C: The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 2012, 31:91. BioMed Central Full Text
• [35]Solivetti MF, Elia F, Graceffa D, Di Carlo A: Ultrasound morphology of inguinal lymph nodes may not herald an associated pathology. J Exp Clin Cancer Res 2012, 31:88. BioMed Central Full Text
• [36]Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM: Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res 2011, 30:10. BioMed Central Full Text
• [37]von Akooi AC, Verhoef C, Eggermont AM: Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol 2010, 7(8):446-454.
• [38]Nagaraja V, Eslick GD: Is complete lymph node dissection after a positive sentinel lymoh node biopsy for cutaneous melanoma always necessary? A meta-analysis. Eur J Surg Oncol 2013, 39(7):669-680.